Partner Randy D. Gordon, chair of the Firm’s antitrust and trade regulation practice, authored an article for Law360 regarding the antitrust issues associated with the Bayer-Monsanto deal.
“Bayer can make a credible case that it and Monsanto are not — for the most part — competitors in the two market dimensions that count in any antitrust analysis. First, with respect to product markets, Bayer has focused on herbicides in the agricultural space, whereas Monsanto has focused on seeds and genetic technology.”
订阅用户可在此处阅读全文。
相关见解
December 12, 2025
Health Care Law Today
Eleventh Circuit Hears Oral Argument in Landmark Constitutional Challenge to False Claims Act’s Qui Tam Provisions
On December 12, the U.S. Court of Appeals for the Eleventh Circuit heard oral argument in U.S. ex rel. Zafirov v. Florida Medical…
2025年12月11日
福莱观点
知识产权组合管理中的反垄断风险与合规策略
本文分析了知识产权组合管理如何在促进创新的同时，也可能带来潜在风险……
2025年12月11日
福莱观点
加州空气资源委员会发布SB 261和SB 253法案的拟议法规
2025年12月9日，加州空气资源委员会（CARB）发布了其针对初始法规的拟议监管文本……